-

Exact Sciences Earns 2025 Great Place To Work® Certification™

Award marks seventh consecutive year company has received prestigious distinction

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.

“Exact Sciences is proud to be recognized as a Great Place To Work for the seventh year in a row—an honor that reflects the passion, integrity, and drive for innovation of our incredible team,” said Sarah Condella.

Share

The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences’ culture, work environment, and leadership. This year, 77% of employees called Exact Sciences a Great Place To Work – 20 points higher than the average U.S.-based company. Great Place To Work is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation.

“Exact Sciences is proud to be recognized as a Great Place To Work for the seventh year in a row—an honor that reflects the passion, integrity, and drive for innovation of our incredible team,” said Sarah Condella, executive vice president of human resources at Exact Sciences. “Our purpose of eradicating cancer guides everything we do, and we’re committed to creating a workplace where everyone feels respected, included, and empowered.”

By achieving this distinction, Exact Sciences joins an elite group of organizations that have demonstrated exceptional workplace practices, a willingness to act on employee feedback, and a strong commitment to employee well-being. The anonymous feedback collected during certification focuses on factors known to impact the quality of an employee’s experience, such as trust, pride, respect, and camaraderie.

“Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,” says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. “By successfully earning this recognition, it is evident that Exact Sciences stands out as one of the top companies to work for, providing a great workplace environment for its employees.”

According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a certified great workplace and 15 times more likely to choose to work at a certified great workplace. Additionally, employees at certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to be paid fairly, to earn a fair share of the company’s profits, and to have a fair chance at promotion.

Exact Sciences is looking for talented people who are passionate about fighting cancer. For more information and to view a complete list of job openings, visit the company careers site.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

NOTE: Exact Sciences and Cologuard are trademarks of Exact Sciences Corporation. Oncotype is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences.

About Great Place To Work® Certification™

Great Place To Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

About Great Place To Work®

As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at greatplacetowork.com and follow Great Place To Work on LinkedIn, Twitter, Facebook and Instagram.

Contacts

Media Contact (U.S.):
Blair Brophy
+1 608-630-7391
bbrophy@exactsciences.com

Investor Contact:
Derek Leckow
608-893-0009
investorrelations@exactsciences.com

Exact Sciences Corp.

NASDAQ:EXAS

Release Versions

Contacts

Media Contact (U.S.):
Blair Brophy
+1 608-630-7391
bbrophy@exactsciences.com

Investor Contact:
Derek Leckow
608-893-0009
investorrelations@exactsciences.com

More News From Exact Sciences Corp.

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie...

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests...

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with s...
Back to Newsroom